OncoMatch/Clinical Trials/NCT07705334
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
Is NCT07705334 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies SHY-ONC6 for advanced or metastatic solid tumors.
Treatment: SHY-ONC6 — This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors who have progressed on or are intolerant to standard therapies. The study will consist of 2 parts: a dose escalation part (Phase 1a) and a dose expansion part (Phase 1b).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Triple-Negative Breast Cancer
Breast Carcinoma
Colorectal Cancer
Gastric Cancer
Non-Small Cell Lung Carcinoma
Mesothelioma
Pancreatic Cancer
Prostate Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
ECOG performance status 0-1
Prior therapy
Must have received: standard therapy
solid tumors that have progressed on or are intolerant/unsuitable for standard therapies
Lab requirements
Blood counts
Adequate organ/bone marrow function
Kidney function
Adequate organ/bone marrow function
Liver function
Adequate organ/bone marrow function
Adequate organ/bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- SCRI at HCA HealthONE · Denver, Colorado
- The University of Texas MD Anderson Cancer Center · Houston, Texas
- NEXT Oncology · San Antonio, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07705334 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify